Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
Contenido proporcionado por Proactive Investors. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Proactive Investors o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Player FM : aplicación de podcast
¡Desconecta con la aplicación Player FM !
¡Desconecta con la aplicación Player FM !
Tryptamine Therapeutics Begins Phase 2a Trial for IBS Treatment at MGH
MP3•Episodio en casa
Manage episode 430778395 series 2891889
Contenido proporcionado por Proactive Investors. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Proactive Investors o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Tryptamine Therapeutics Ltd (ASX: TYP) president and chief scientific officer Jim Gilligan joins Jonathan Jackson in the Proactive studio to discuss the company’s Phase 2a clinical trial at Massachusetts General Hospital (MGH) in the US, targeting the treatment of Irritable Bowel Syndrome (IBS). The trial involves administering oral psilocybin, known as TRP-8802, combined with psychotherapy. MGH, part of the Mass General Brigham health system and Harvard's oldest hospital, is participating in this study for the first time. Up to ten patients will receive the treatment, with primary efficacy endpoints focused on reducing chronic abdominal pain and visceral tenderness. Results are anticipated in the first quarter of 2025. This trial will guide further research on TRP-8803, an IV-infused psilocin, expected to offer improved efficacy, safety, faster onset, precise control, and reduced intervention duration compared to oral psilocybin. IBS affects up to 20% of Australians and 15% of the US population and represents a significant unmet medical need, impacting productivity and quality of life. Tryptamine Therapeutics aims to address this need by exploring the gut-brain relationship through their ongoing and future clinical trials. Gilligan highlighted the collaboration with MGH, noting its prestigious reputation and significant interest in psychedelic compounds for treating unmet medical needs. Tryptamine Therapeutics is also advancing clinical trials for other conditions, including binge eating disorder and fibromyalgia. #ProactiveInvestors #ASX #TryptamineTherapeutics #IBS #ClinicalTrial #Psilocybin #TRP8802 #MassGeneralHospital #MGH #Harvard #GutBrainRelationship #Psychotherapy #TRP8803 #PsychedelicResearch #UnmetMedicalNeed #Productivity #QualityOfLife #Biotech #HealthcareInnovation #MentalHealth #BingeEatingDisorder #Fibromyalgia #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 episodios
MP3•Episodio en casa
Manage episode 430778395 series 2891889
Contenido proporcionado por Proactive Investors. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Proactive Investors o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Tryptamine Therapeutics Ltd (ASX: TYP) president and chief scientific officer Jim Gilligan joins Jonathan Jackson in the Proactive studio to discuss the company’s Phase 2a clinical trial at Massachusetts General Hospital (MGH) in the US, targeting the treatment of Irritable Bowel Syndrome (IBS). The trial involves administering oral psilocybin, known as TRP-8802, combined with psychotherapy. MGH, part of the Mass General Brigham health system and Harvard's oldest hospital, is participating in this study for the first time. Up to ten patients will receive the treatment, with primary efficacy endpoints focused on reducing chronic abdominal pain and visceral tenderness. Results are anticipated in the first quarter of 2025. This trial will guide further research on TRP-8803, an IV-infused psilocin, expected to offer improved efficacy, safety, faster onset, precise control, and reduced intervention duration compared to oral psilocybin. IBS affects up to 20% of Australians and 15% of the US population and represents a significant unmet medical need, impacting productivity and quality of life. Tryptamine Therapeutics aims to address this need by exploring the gut-brain relationship through their ongoing and future clinical trials. Gilligan highlighted the collaboration with MGH, noting its prestigious reputation and significant interest in psychedelic compounds for treating unmet medical needs. Tryptamine Therapeutics is also advancing clinical trials for other conditions, including binge eating disorder and fibromyalgia. #ProactiveInvestors #ASX #TryptamineTherapeutics #IBS #ClinicalTrial #Psilocybin #TRP8802 #MassGeneralHospital #MGH #Harvard #GutBrainRelationship #Psychotherapy #TRP8803 #PsychedelicResearch #UnmetMedicalNeed #Productivity #QualityOfLife #Biotech #HealthcareInnovation #MentalHealth #BingeEatingDisorder #Fibromyalgia #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 episodios
Усі епізоди
×Bienvenido a Player FM!
Player FM está escaneando la web en busca de podcasts de alta calidad para que los disfrutes en este momento. Es la mejor aplicación de podcast y funciona en Android, iPhone y la web. Regístrate para sincronizar suscripciones a través de dispositivos.